POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo targets Tough-to-Treat blood cancer
Disease control Not yet recruitingThis study is testing whether a combination of two drugs, pacritinib and selinexor, can help control myelofibrosis in patients who have not yet tried a common type of treatment (JAK inhibitors) and who have low red blood cell and platelet counts. The main goals are to see if the …
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Major cancer registry launches to track Real-World blood cancer treatments
Knowledge-focused Not yet recruitingThis study is creating a national registry to track how 200 patients with myelofibrosis (a rare bone marrow cancer) and anemia are treated in real-world German clinics. It will follow patients for up to three years to document which treatment sequences doctors use, how patients r…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:33 UTC